10-Q: Vycor Medical Q1 2026 Financial Results

Vycor Medical reported a net income of $20,108 for the first quarter of 2026, though substantial doubt remains regarding its ability to continue as a going concern.

Summary

• Revenue for Q1 2026 was $458,540, a 5% increase compared to $436,378 in Q1 2025.
• Net income for the quarter was $20,108, compared to a net loss of $38,563 in the prior year period.
• Operating income reached $45,808, reversing an operating loss of $12,806 in Q1 2025.
• The company maintains a significant working capital deficiency of $4,297,001 as of March 31, 2026.
• Related party liabilities total $3,833,138, including substantial accrued dividends and interest.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a high-risk situation; while the company achieved a small profit, the persistent going concern warning and massive working capital deficit overshadow operational improvements.

Positives

• Revenue grew by 5% year-over-year, driven primarily by international market expansion.
• Achieved a return to profitability with net income of $20,108 for the quarter.
• Operating expenses decreased to $329,345 from $371,340 in the same period last year.
• Gross profit margin remains strong at 82% for the Vycor Medical segment.

Negatives

• The company faces a severe working capital deficiency of over $4.29 million.
• Accumulated deficit stands at $33,790,933.
• Significant reliance on related party funding from Fountainhead Capital Management Limited.
• Material weakness in internal controls persists due to the lack of a functioning independent audit committee.

Risks

• Substantial doubt exists regarding the company's ability to continue as a going concern.
• A $300,000 term note plus $580,866 in accrued interest is due on June 30, 2026, with no guarantee of extension.
• Insufficient cash to meet operational needs through May 31, 2027 without additional financing.
• Concentration risk: 35% of accounts receivable is tied to three customers.

Future Outlook

The company is focused on revenue growth through increased US market penetration and international expansion. Management is exploring strategic alternatives for the NovaVision segment, including partnerships, licensing, or sale, while seeking additional debt or equity funding to address liquidity needs.

Management Comments

• Management believes it may not have sufficient cash to meet its various cash needs through May 31, 2027 without additional capital.
• The company is executing a plan to achieve a reduction in operating losses.

Industry Context

StockSavvy.ai notes that Vycor operates in a niche medical device market where high regulatory barriers and capital intensity often lead to consolidation or reliance on private equity backing, as evidenced by the company's heavy dependence on Fountainhead Capital.

Comparison to Industry Standards

• The company's reliance on related-party debt is significantly higher than typical industry standards for publicly traded medical device firms.
• The lack of an independent audit committee is a major governance outlier compared to standard SEC-listed company requirements.

Corporate Governance

Legal Proceedings

• None reported as of May 14, 2026.

Related Party Transactions

• Significant debt and accrued dividends owed to Fountainhead Capital Management Limited and Peter Zachariou.

Stakeholder Impact

• Shareholders face dilution risk if the company issues new equity to address the working capital deficit.
• Creditors are exposed to high risk given the going concern status.

Next Steps

• Negotiate potential extension of the $300,000 EuroAmerican note due June 30, 2026.
• Continue efforts to secure additional debt or equity financing.
• Evaluate strategic alternatives for the NovaVision business unit.

Key Dates

Recommendation

The company's precarious financial position, characterized by a severe working capital deficit and a going concern warning, makes it an unsuitable investment for most institutional or retail investors until a sustainable capital structure is established.

Keywords

Vycor Medical, VYCO, neurosurgery, medical devices, NovaVision, going concern, small-cap